Document Type
Article
Publication Date
4-2022
Abstract
Serine/threonine kinases mediate the phosphorylation of intracellular protein targets, transferring a phosphorus group from an adenosine triphosphate molecule to the specific amino acid residues within the target proteins. Serine/threonine kinases regulate multiple key cellular functions. From this large group of kinases, TGF-β through serine/threonine activity of its receptors and Rho kinase (ROCK) play an important role in the development and maintenance of fibrosis in various human diseases, including SSc. In recent years, multiple drugs targeting and inhibiting these kinases have been developed, opening the possibility of becoming potential antifibrotic agents of clinical value for treating fibrotic diseases. This review analyses the contribution of TGF-β and ROCK-mediated serine/threonine kinase molecular pathways to the development and maintenance of pathological fibrosis and the potential clinical use of their inhibition
Recommended Citation
Mendoza, Fabian A. and Jimenez, Sergio A., "Serine-threonine kinase inhibition as antifibrotic therapy: transforming growth factor-β and Rho kinase inhibitors" (2022). Scleroderma Center Faculty Papers. Paper 8.
https://jdc.jefferson.edu/sclerodermafp/8
Language
English
Comments
This is the authors' accepted manuscript from the journal Rheumatology, Volume 61, Issue 4, April 2022, Pages 1354–1365.
The final published version of the article can be found at the journal's website: https://doi.org/10.1093/rheumatology/keab762